董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan Chen | 男 | Director | 42 | 未披露 | 未持股 | 2017-05-01 |
| HongBin Sun | 男 | Director | 46 | 未披露 | 未持股 | 2017-05-01 |
| Michael H. Carrel | 男 | Director | 46 | 7.05万 | 未持股 | 2017-05-01 |
| Raymond W. Cohen | 男 | Chairman of the Board of Directors | 57 | 14.62万 | 未持股 | 2017-05-01 |
| John Rush | 男 | Director | 58 | 6.66万 | 未持股 | 2017-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kurt Lemvigh | 男 | Chief Executive Officer | 49 | 未披露 | 未持股 | 2017-05-01 |
| William J. Kullback | 男 | Chief Financial Officer | 57 | 40.75万 | 未持股 | 2017-05-01 |
| Peter Phillips | 男 | Chief Technology Officer | 58 | 29.21万 | 未持股 | 2017-05-01 |
董事简历
中英对照 | 中文 | 英文- Jonathan Chen
-
Jonathan Chen先生，1975年出生，美国国籍，斯坦福大学的经济学学士学位和生物科学荣誉学士学位，曾就职于Credit Suisse担任投资银行部副总裁，于Angiotech制药公司担任商业发展及财务战略部资深副总裁，于2012年加入微创医疗科学有限公司担任国际业务与投资者关系执行副总裁，现任微创医疗科学有限公司首席国际业务官，洲际心律管理委员会主席，洲际骨科执行委员会委员。2023年11月至今，担任心脉医疗董事长。
Mr. Jonathan Chen was born in 1975 and holds American citizenship. He has a Bachelor of Arts in Economics and a Bachelor of Arts in Biological Sciences with Honors from Stanford University. He once worked as a Vice President in the Investment Banking Department of Credit Suisse and as a Senior Vice President in the Business Development and Financial Strategy Department of Angiotech Pharmaceuticals. In 2012, he joined MicroPort Scientific Corporation and served as the Executive Vice President of International Business and Investor Relations. Currently, he serves as the Chief International Business Officer of MicroPort Scientific Corporation, the Chairman of the InterContinental Cardiac Rhythm Management Committee, and a member of the Executive Committee of InterContinental Orthopedics. Since November 2023, he has been serving as the Chairman of the Board of Shanghai MicroPort Endovascular MedTech Co., Ltd. - Jonathan Chen先生，1975年出生，美国国籍，斯坦福大学的经济学学士学位和生物科学荣誉学士学位，曾就职于Credit Suisse担任投资银行部副总裁，于Angiotech制药公司担任商业发展及财务战略部资深副总裁，于2012年加入微创医疗科学有限公司担任国际业务与投资者关系执行副总裁，现任微创医疗科学有限公司首席国际业务官，洲际心律管理委员会主席，洲际骨科执行委员会委员。2023年11月至今，担任心脉医疗董事长。
- Mr. Jonathan Chen was born in 1975 and holds American citizenship. He has a Bachelor of Arts in Economics and a Bachelor of Arts in Biological Sciences with Honors from Stanford University. He once worked as a Vice President in the Investment Banking Department of Credit Suisse and as a Senior Vice President in the Business Development and Financial Strategy Department of Angiotech Pharmaceuticals. In 2012, he joined MicroPort Scientific Corporation and served as the Executive Vice President of International Business and Investor Relations. Currently, he serves as the Chief International Business Officer of MicroPort Scientific Corporation, the Chairman of the InterContinental Cardiac Rhythm Management Committee, and a member of the Executive Committee of InterContinental Orthopedics. Since November 2023, he has been serving as the Chairman of the Board of Shanghai MicroPort Endovascular MedTech Co., Ltd.
- HongBin Sun
-
HongBin Sun于2016年12月18日加入董事会。他是Microport Scientific的首席财务官、CEC的联合主席和IEC的成员。孙先生目前在Microport Scientific的子公司上海Microport骨科有限公司担任执行董事职务。Sun从2006年到2010年7月担任Otsuka China董事和总经理。从2004年到2006年，他担任Otsuka China公司的财务董事。从1998年到2003年，孙先生是毕马威会计师事务所上海办事处的助理经理。孙先生是中国注册会计师协会会员，也是特许金融分析师。孙先生于1998年在中国上海交通大学获得经济学学士学位。
HongBin Sun joined the Board on December 18 2016. He serves as the Chief Financial Officer of MicroPort Scientific, the Co-Chairperson of CEC and a member of IEC. Mr. Sun is currently holding the executive directorship in Shanghai MicroPort Orthopedics Co., Ltd., a subsidiary of the MicroPort Scientific. Mr. Sun was the Director and General Manager of Otsuka China from 2006 to July 2010. From 2004 to 2006 he served as a Financial Director of Otsuka China. From 1998 to 2003 Mr. Sun was an Assistant Manager of the Shanghai office of KPMG. Mr. Sun is a member of the Chinese Institute of Certified Public Accountants and is also a Chartered Financial Analyst. Mr. Sun received his bachelor’s degree in Economics from Shanghai Jiao Tong University in China in 1998. - HongBin Sun于2016年12月18日加入董事会。他是Microport Scientific的首席财务官、CEC的联合主席和IEC的成员。孙先生目前在Microport Scientific的子公司上海Microport骨科有限公司担任执行董事职务。Sun从2006年到2010年7月担任Otsuka China董事和总经理。从2004年到2006年，他担任Otsuka China公司的财务董事。从1998年到2003年，孙先生是毕马威会计师事务所上海办事处的助理经理。孙先生是中国注册会计师协会会员，也是特许金融分析师。孙先生于1998年在中国上海交通大学获得经济学学士学位。
- HongBin Sun joined the Board on December 18 2016. He serves as the Chief Financial Officer of MicroPort Scientific, the Co-Chairperson of CEC and a member of IEC. Mr. Sun is currently holding the executive directorship in Shanghai MicroPort Orthopedics Co., Ltd., a subsidiary of the MicroPort Scientific. Mr. Sun was the Director and General Manager of Otsuka China from 2006 to July 2010. From 2004 to 2006 he served as a Financial Director of Otsuka China. From 1998 to 2003 Mr. Sun was an Assistant Manager of the Shanghai office of KPMG. Mr. Sun is a member of the Chinese Institute of Certified Public Accountants and is also a Chartered Financial Analyst. Mr. Sun received his bachelor’s degree in Economics from Shanghai Jiao Tong University in China in 1998.
- Michael H. Carrel
-
Michael H. Carrel，他担任主席，首席执行官和董事（2012年11月以来）。他担任Vital Images（上市医疗成像软件公司）的总裁兼首席执行官（从2008年到2012年）。他最初于2005年1月加入Vital Images，担任首席运营官和首席财务官。在Vital Images 任职期间，他领导公司成为保健和医疗软件行业的领导者。在他的领导下，公司的收入和利润增长，全球市场份额增加，遍布90多个国家，并股权融资筹集了1亿美元。此前，他担任Zamba集团（上市科技公司）的总裁兼首席执行官，以及NextNet Wireless（即插即用宽带无线接入系统的私人供应商，现在属于摩托罗拉公司）的首席财务官。他拥有宾夕法尼亚州立大学会计学士学位和宾夕法尼亚大学的沃顿商学院的工商管理学硕士学位。
Michael H. Carrel has served as President, Chief Executive Officer and director since November 2012. Since joining AtriCure, Mr. Carrel has fostered a patient-first company approach by focusing on the three core areas: innovation, clinical science and education. This strategic approach has led AtriCure to significantly invest in groundbreaking clinical trials for the treatment of atrial fibrillation Afib, left atrial appendage management and pain management; expand its market presence within Europe and Asia; and grow the global employee base from 200 to over 700 employees. In addition, during Mike’s tenure, AtriCure has acquired three companies, Estech, nContact, and SentreHEART, adding leading ablation and appendage management technologies to further AtriCure’s market position worldwide. Before joining AtriCure, Mr. Carrel served as President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company that was sold to Toshiba in 2011. Prior to Vital Images, Mr. Carrel was President and CEO of Zamba Corporation, a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug and play broadband wireless access systems. Mr. Carrel recently served as a director of Lombard Medical until acquired by MicroPort Scientific Corporation in 2018. Mr. Carrel currently serves on the board of the Medical Device Manufacturers Association (MDMA) and Axonics Modulation Technologies, Inc. a medical device company focused on the treatment of urinary and bowel dysfunction. Mr. Carrel holds a B.S. in Accounting from The Pennsylvania State University and an M.B.A. from The Wharton School at the University of Pennsylvania. - Michael H. Carrel，他担任主席，首席执行官和董事（2012年11月以来）。他担任Vital Images（上市医疗成像软件公司）的总裁兼首席执行官（从2008年到2012年）。他最初于2005年1月加入Vital Images，担任首席运营官和首席财务官。在Vital Images 任职期间，他领导公司成为保健和医疗软件行业的领导者。在他的领导下，公司的收入和利润增长，全球市场份额增加，遍布90多个国家，并股权融资筹集了1亿美元。此前，他担任Zamba集团（上市科技公司）的总裁兼首席执行官，以及NextNet Wireless（即插即用宽带无线接入系统的私人供应商，现在属于摩托罗拉公司）的首席财务官。他拥有宾夕法尼亚州立大学会计学士学位和宾夕法尼亚大学的沃顿商学院的工商管理学硕士学位。
- Michael H. Carrel has served as President, Chief Executive Officer and director since November 2012. Since joining AtriCure, Mr. Carrel has fostered a patient-first company approach by focusing on the three core areas: innovation, clinical science and education. This strategic approach has led AtriCure to significantly invest in groundbreaking clinical trials for the treatment of atrial fibrillation Afib, left atrial appendage management and pain management; expand its market presence within Europe and Asia; and grow the global employee base from 200 to over 700 employees. In addition, during Mike’s tenure, AtriCure has acquired three companies, Estech, nContact, and SentreHEART, adding leading ablation and appendage management technologies to further AtriCure’s market position worldwide. Before joining AtriCure, Mr. Carrel served as President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company that was sold to Toshiba in 2011. Prior to Vital Images, Mr. Carrel was President and CEO of Zamba Corporation, a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug and play broadband wireless access systems. Mr. Carrel recently served as a director of Lombard Medical until acquired by MicroPort Scientific Corporation in 2018. Mr. Carrel currently serves on the board of the Medical Device Manufacturers Association (MDMA) and Axonics Modulation Technologies, Inc. a medical device company focused on the treatment of urinary and bowel dysfunction. Mr. Carrel holds a B.S. in Accounting from The Pennsylvania State University and an M.B.A. from The Wharton School at the University of Pennsylvania.
- Raymond W. Cohen
-
Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
Raymond W. Cohen,Prior to joining Kestra as a director, from 2013 to late 2024, Mr. Cohen served as the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, which was sold to Boston Scientific Corporation (NYSE: BSX) in November 2024. From 2023 to 2025, Mr. Cohen served as the chairman of the board of directors of SoniVie Ltd until it was acquired by Boston Scientific Corporation in March 2025. Mr. Cohen currently serves as chairman of the boards of directors of the privately held companies Nalu Medical Inc. and Archimedes Vascular, vice chairman of the board of directors of the privately held company Tulavi Medical, and a member of the board of directors of the private equity sponsor-backed company Spectrum Vascular. Previously, Mr. Cohen served as chairman of the board of directors of BioLife Solutions Inc. (Nasdaq: BLFS) and as a director of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI). Mr. Cohen received his B.S. in Business Management from Binghamton University. - Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
- Raymond W. Cohen,Prior to joining Kestra as a director, from 2013 to late 2024, Mr. Cohen served as the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, which was sold to Boston Scientific Corporation (NYSE: BSX) in November 2024. From 2023 to 2025, Mr. Cohen served as the chairman of the board of directors of SoniVie Ltd until it was acquired by Boston Scientific Corporation in March 2025. Mr. Cohen currently serves as chairman of the boards of directors of the privately held companies Nalu Medical Inc. and Archimedes Vascular, vice chairman of the board of directors of the privately held company Tulavi Medical, and a member of the board of directors of the private equity sponsor-backed company Spectrum Vascular. Previously, Mr. Cohen served as chairman of the board of directors of BioLife Solutions Inc. (Nasdaq: BLFS) and as a director of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI). Mr. Cohen received his B.S. in Business Management from Binghamton University.
- John Rush
-
John Rush 他是一名在医疗器械行业有30年工作经验的主管。目前担任总部设在德克萨斯州奥斯汀的Inova公司实验室首席执行官。此前，自2009年至2011年初期间，他担任伦巴医疗技术公司首席执行官。2003年，在伦巴公司任职期间，本公司顺利通过在美国的IDE PMA试验，此次的成功直接影响了美国食品及药物管理局批准其AAA级干细胞移植。加入隆巴德之前，曾担任北美科技公司纳斯达克总裁兼首席执行官。他还担任过在美国和欧洲MicroTherapeutics公司的首席执行官。（纳斯达克股票代码：MTIX），这是一家介入神经放射学公司。 MTIX公司被EV3公司并购后成为Covidien公司医疗产品组合的一部分。在加入MTIX公司之前，他在Scimed生命系统/波士顿科学公司担任各种管理职务10多年，包括波士顿科技公司（其总部设在新加坡的亚太）的业务总经理。
John Rush currently serves as Chief Executive Officer of Inova Labs based in Austin, TX. Previously, Mr. Rush served as Chief Executive Officer of Lombard Medical Technologies PLC from 2009 to early 2011. During his tenure at Lombard, the Company successfully navigated through an IDE PMA trial in the United States which led to FDA approval for its AAA stent-graft in early 2013. Before joining Lombard, Mr. Rush was President and CEO of North American Scientific, Inc. Nasdaq: NASM and he also served as President and CEO of Micro Therapeutics, Inc. (Nasdaq: MTIX), an interventional neuroradiology company with operations in the United States and Europe. MTIX was purchased by ev3 and subsequent to that became a part of the Covidien Healthcare portfolio. Prior to MTIX, Mr. Rush spent 10 years with Scimed Life Systems/Boston Scientific in various management roles, including General Manager of Boston Scientific’s Asia Pacific business based in Singapore. - John Rush 他是一名在医疗器械行业有30年工作经验的主管。目前担任总部设在德克萨斯州奥斯汀的Inova公司实验室首席执行官。此前，自2009年至2011年初期间，他担任伦巴医疗技术公司首席执行官。2003年，在伦巴公司任职期间，本公司顺利通过在美国的IDE PMA试验，此次的成功直接影响了美国食品及药物管理局批准其AAA级干细胞移植。加入隆巴德之前，曾担任北美科技公司纳斯达克总裁兼首席执行官。他还担任过在美国和欧洲MicroTherapeutics公司的首席执行官。（纳斯达克股票代码：MTIX），这是一家介入神经放射学公司。 MTIX公司被EV3公司并购后成为Covidien公司医疗产品组合的一部分。在加入MTIX公司之前，他在Scimed生命系统/波士顿科学公司担任各种管理职务10多年，包括波士顿科技公司（其总部设在新加坡的亚太）的业务总经理。
- John Rush currently serves as Chief Executive Officer of Inova Labs based in Austin, TX. Previously, Mr. Rush served as Chief Executive Officer of Lombard Medical Technologies PLC from 2009 to early 2011. During his tenure at Lombard, the Company successfully navigated through an IDE PMA trial in the United States which led to FDA approval for its AAA stent-graft in early 2013. Before joining Lombard, Mr. Rush was President and CEO of North American Scientific, Inc. Nasdaq: NASM and he also served as President and CEO of Micro Therapeutics, Inc. (Nasdaq: MTIX), an interventional neuroradiology company with operations in the United States and Europe. MTIX was purchased by ev3 and subsequent to that became a part of the Covidien Healthcare portfolio. Prior to MTIX, Mr. Rush spent 10 years with Scimed Life Systems/Boston Scientific in various management roles, including General Manager of Boston Scientific’s Asia Pacific business based in Singapore.
高管简历
中英对照 | 中文 | 英文- Kurt Lemvigh
Kurt Lemvigh是我们的首席执行官，自2017年4月20日起担任该职位。他目前居住在英国，曾担任多种公共和私人公司的高级销售、营销和运营职务，包括Spacelabs公司、Cardiac Science公司、GE公司和Marquette-Hellige公司。除了欧洲和美国，Lemvigh先生还在世界各地的众多国际市场开展业务，包括中东、日本、中国、印度和拉丁美洲。Lemvigh先生在丹麦Neils Brock Business University获得销售与市场营销学士学位。
Kurt Lemvigh is our Chief Executive Officer and has held that position since April 20 2017. He currently resides in the U.K. and has held senior sales, marketing and operational positions at various public and private companies including Spacelabs, Cardiac Science, GE and Marquette-Hellige. In addition to Europe and the United States, Mr. Lemvigh has conducted business in numerous international markets around the world including the Middle East, Japan, China, India and Latin America. Mr. Lemvigh received a B.A. in sales and marketing from Neils Brock Business University in Denmark.- Kurt Lemvigh是我们的首席执行官，自2017年4月20日起担任该职位。他目前居住在英国，曾担任多种公共和私人公司的高级销售、营销和运营职务，包括Spacelabs公司、Cardiac Science公司、GE公司和Marquette-Hellige公司。除了欧洲和美国，Lemvigh先生还在世界各地的众多国际市场开展业务，包括中东、日本、中国、印度和拉丁美洲。Lemvigh先生在丹麦Neils Brock Business University获得销售与市场营销学士学位。
- Kurt Lemvigh is our Chief Executive Officer and has held that position since April 20 2017. He currently resides in the U.K. and has held senior sales, marketing and operational positions at various public and private companies including Spacelabs, Cardiac Science, GE and Marquette-Hellige. In addition to Europe and the United States, Mr. Lemvigh has conducted business in numerous international markets around the world including the Middle East, Japan, China, India and Latin America. Mr. Lemvigh received a B.A. in sales and marketing from Neils Brock Business University in Denmark.
- William J. Kullback
William J. Kullback于2008年3月17日被任命为Angeion的首席财务官兼高级副总裁。加入该公司前，Kullback先生担任 Flex Fund Financial的联合创始人和首席财务官，这是一家私有的金融服务公司。从2005年4月到2006年5月，Kullback 担任IntriCon Corporation的首席财务官，这是一家上市的制造商，专注于高技术医疗设备与通信行业。从2002年11月到MedSource Technologies, Inc.于2004年9月被出售，Kullback还担任其高级副总裁兼首席财务官，并担任PEMSTAR, Inc.的执行副总裁和首席财务官，这是一家公共工程与制造服务公司。在这之前，Kullback先生担任过Crenlo, Inc.、 Stant Corporation与普华永道会计师事务所（PriceWaterhouse）的多个财务与会计职位。 Kullback先生还担任Reptron Electronics的董事，他在该公司担任审计委员会主席，并参与该上市制造公司的出售。Kullback先生在布法罗的纽约州立大学（State University of New York）获得工商管理硕士学位与文学学士学位。
William J. Kullback is our Chief Financial Officer, having joined the company in December 2014. Most recently, he served as partner, chief financial officer and chief compliance officer of Integris, LLC, a SEC-registered wealth management firm with more than $300 million in assets under management. Mr. Kullback received a B.A. in economics and English, as well as an MBA with a concentration in accounting, from the State University of New York at Buffalo.- William J. Kullback于2008年3月17日被任命为Angeion的首席财务官兼高级副总裁。加入该公司前，Kullback先生担任 Flex Fund Financial的联合创始人和首席财务官，这是一家私有的金融服务公司。从2005年4月到2006年5月，Kullback 担任IntriCon Corporation的首席财务官，这是一家上市的制造商，专注于高技术医疗设备与通信行业。从2002年11月到MedSource Technologies, Inc.于2004年9月被出售，Kullback还担任其高级副总裁兼首席财务官，并担任PEMSTAR, Inc.的执行副总裁和首席财务官，这是一家公共工程与制造服务公司。在这之前，Kullback先生担任过Crenlo, Inc.、 Stant Corporation与普华永道会计师事务所（PriceWaterhouse）的多个财务与会计职位。 Kullback先生还担任Reptron Electronics的董事，他在该公司担任审计委员会主席，并参与该上市制造公司的出售。Kullback先生在布法罗的纽约州立大学（State University of New York）获得工商管理硕士学位与文学学士学位。
- William J. Kullback is our Chief Financial Officer, having joined the company in December 2014. Most recently, he served as partner, chief financial officer and chief compliance officer of Integris, LLC, a SEC-registered wealth management firm with more than $300 million in assets under management. Mr. Kullback received a B.A. in economics and English, as well as an MBA with a concentration in accounting, from the State University of New York at Buffalo.
- Peter Phillips
Peter Phillips 他是我公司的技术总监，并从2011年1月1日起担任伦巴第的董事会董事。他是伦敦盖伊医院的博士。自1995年起，由他共同开发了Aorfix干细胞移植术，并且直接有助于Aorfix的开发和商业化。他是我们公司技术及其临床应用方面的专家。 2006年，他移居到美国，成为伦巴第美国分公司主席，分公司主要负责支持Aorfix在美的临床试验。2009年重返英国后，他担任首席技术官。他是一家英国骨科公司（Surgicraft有限公司）的董事长。
Peter Phillips is our Chief Technology Officer. Dr. Phillips has a PhD from Guy’s Hospital in London. Dr. Phillips co-developed the Aorfix stent graft and led the development and commercialization of Aorfix from 1995. He is the Company’s leading expert on the technology and its clinical application. In 2006 Dr. Phillips moved to the United States to become President of Lombard’s U.S. Subsidiary, which was set up to support the Aorfix clinical trial. Upon returning to the United Kingdom in 2009 he took up the position of Chief Technology Officer. Dr. Phillips was a director of Surgicraft Ltd., a UK orthopedics company.- Peter Phillips 他是我公司的技术总监，并从2011年1月1日起担任伦巴第的董事会董事。他是伦敦盖伊医院的博士。自1995年起，由他共同开发了Aorfix干细胞移植术，并且直接有助于Aorfix的开发和商业化。他是我们公司技术及其临床应用方面的专家。 2006年，他移居到美国，成为伦巴第美国分公司主席，分公司主要负责支持Aorfix在美的临床试验。2009年重返英国后，他担任首席技术官。他是一家英国骨科公司（Surgicraft有限公司）的董事长。
- Peter Phillips is our Chief Technology Officer. Dr. Phillips has a PhD from Guy’s Hospital in London. Dr. Phillips co-developed the Aorfix stent graft and led the development and commercialization of Aorfix from 1995. He is the Company’s leading expert on the technology and its clinical application. In 2006 Dr. Phillips moved to the United States to become President of Lombard’s U.S. Subsidiary, which was set up to support the Aorfix clinical trial. Upon returning to the United Kingdom in 2009 he took up the position of Chief Technology Officer. Dr. Phillips was a director of Surgicraft Ltd., a UK orthopedics company.